Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

SUPPORT-E

Financiado

Cerrado

SUPporting high quality evaluation of COVID 19 convalescent Plasma thrOughoutT E...

SUPporting high quality evaluation of COVID 19 convalescent Plasma thrOughoutT Europe Coronavirus disease 19 (COVID-19) is provoking the greatest global health crisis of this generation. With no vaccine or specific antiviral treatment available to date, the use of convalescent plasma (CP) from recovered COVID-19 pa... ver más

31/12/2025

EUROPEAN BLOOD ALL...

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

EUROPEAN BLOOD ALLIANCE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 12 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-09-02 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

12 Participantes

EUROPEAN BLOOD ALLIANCE

279.93K€ | Lider

SSI

37.24K€ | Participante

ISTITUTO SUPERIORE DI SANITA

97.36K€ | Participante

BLUTSPENDE SRK SCHWEIZ AG

27.03K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

EVIDENT Ebola Virus Disease correlates of protection determinants... 2M€ Cerrado

ISIDORe Integrated Services for Infectious Disease Outbreak Research 21M€ Cerrado

PID2021-127496NB-I00 ANALISIS DE LAS BASES MOLECULARES DE LA INTERACCION SARS-COV... 133K€ Cerrado

EU-RESPONSE European Research and Preparedness Network for Pandemics and... 16M€ Cerrado

EPIC-CROWN-2 Equine Polyclonal antibodies Immunotherapy against COVID-19/... 9M€ Cerrado

Duración del proyecto: 63 meses Fecha Inicio: 2020-09-02
Fecha Fin: 2025-12-31

Líder del proyecto

EUROPEAN BLOOD ALLIANCE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Coronavirus disease 19 (COVID-19) is provoking the greatest global health crisis of this generation. With no vaccine or specific antiviral treatment available to date, the use of convalescent plasma (CP) from recovered COVID-19 patients has been considered a potential curative strategy. To demonstrate its efficacy and safety, clinical studies are ongoing or planned in various EU Member States. Unfortunately, there lacks a coordinated approach involving a large number of blood establishments (BEs) and clinical centres to harmonise protocols and guidelines, to standardise assays for characterising the potency of the plasma and to validate clinical outcome which will be of great importance to ensure that significant conclusions can be drawn. SUPPORT-E brings together major European BEs with world leading research capabilities with the aim to support high quality clinical and scientific evaluation of COVID-19 CP (CCP) and thereby achieve a consensus on the appropriate use of CCP in the treatment of COVID-19 across EU Member States. Hence, SUPPORT-E will advance the current state-of-the-art by delivering the much needed harmonised evidence-based recommendations with respect to the use of CPP in clinical trials and monitored access programmes for COVID-19 patients in Europe. Further, standardised informative in vitro assays providing scientific insights that could support such recommendations will also be developed. SUPPORT-E offers an EU-wide collaboration between Member States, BEs and clinical centres in order to close the knowledge gap and to ensure applicability of the recommendations for all EU Members States. SUPPORT-E represents the first European Union coordinated research effort on passive immunotherapy, sharing data and protocols in real-time and pooling efforts to decrease the time as much as possible for validating CCP as a valid therapeutic treatment and also providing a basis for further optimisation by combined approaches with other anti-viral treatments.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores